BMY focuses R&D on novel modalities like cell therapies, protein degraders, and ADCs.

{
  "signal_id": "5f6d3ddf-0931-4724-85f6-bb1a243ee0d7",
  "signal_type": "sec-10k",
  "signal_subtype": "platformStrategy",
  "detected_at": "2026-02-17T06:30:02.078+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "detail": "To combat upcoming patent expirations, BMY is concentrating R&D investment in specific disease areas (oncology, immunology, cardiovascular, neuroscience) and advanced technology platforms. This signals a strategic shift and budget allocation towards specialized research tools, manufacturing capabilities, and clinical trial support for these complex modalities.",
    "metrics": {
      "timeframe": "multi_year"
    },
    "summary": "BMY focuses R&D on novel modalities like cell therapies, protein degraders, and ADCs.",
    "excerpts": "We concentrate our R&D efforts in the following disease areas with significant unmet medical needs: oncology and hematology with novel modalities in cell therapies, protein degraders, ADCs and radiopharmaceuticals; immunology with a focus on establishing new standards of care in pulmonology, rapidly advancing cell therapy into immunology diseases and transformational programs to control inflammation, reset immune memory and promote homeostasis in rheumatology disorders; cardiovascular diseases by leveraging deep expertise across thrombotic diseases, heart failures and cardiomyopathies; neuroscience with a focus on developing new treatments in neuropsychiatry and neurodegeneration...",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm",
    "filing_date": "2026-02-11",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Platform tools needed",
    "signal_category": "strategic",
    "technologies_mentioned": [
      "cell therapies",
      "protein degraders",
      "ADCs",
      "radiopharmaceuticals",
      "biologics",
      "CAR-T cell therapies"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/5f6d3ddf-0931-4724-85f6-bb1a243ee0d7 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bms.com","limit":20}'